We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

Geistlich Mucograft® Seal

Geistlich Mucograft® Seal is a ready-to-use matrix with a convenient circular shape. The matrix provides an alternative to soft-tissue grafts. Geistlich Mucograft® Seal is indicated for the sealing of extraction sockets with preserved buccal walls in combination with Geistlich Bio-Oss® Collagen in ridge preservation procedures. The matrix establishes predictable dimensions for soft-tissue management.

 

Leading clinicians rely on Geistlich Mucograft Seal®:

  • Minimal invasion1,2.
  • No harvest site morbidity1.
  • Creates predictable soft-tissue dimensions for later soft-tissue management and allows for flexible timing of implant placement1.
  • Early implant placement possible 8-10 weeks after extraction1.
  • Reduced surgical chair-time compared with autogenous grafts1.
  • Faster soft-tissue wound healing compared with autogenous grafts3.
  • Natural soft-tissue colour and texture match1,3.

 

Geistlich Mucograft® Seal consists of two structures: the compact structure provides stability while allowing open healing; the spongy structure supports blood clot stabilisation and ingrowth of soft-tissue cells.

 

References:

  1. Geistlich Mucograft® Seal Advisory Board Meeting Report, 2013. Data on file, Geistlich Pharma AG, Wolhusen, Switzerland.
  2. Jung R, et al.: J. Clin Periodontol 2013; 40(1): 90-98.
  3. Thoma D, et al.: J. Clin Periodontol 2012; 39: 157-65.

 

Verena Vermeulen
Group Lead Clinical Marketing